Navigation Links
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy
Date:7/23/2009

Efficacy and Safety Study in Patients with Moderate to Severe Post-Operative Pain

SYDNEY, Australia and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. Data from this study will serve as a significant predictor of MoxDuo(TM) IV's clinical benefits and provide guidance for the design of further clinical trials leading to submission of an NDA to the US Food and Drug Administration (FDA) within the next three years.

"QRxPharma's goal is to bring to market complementary analgesic options for pain specialists, delivering greater patient tolerability and efficacy than current standards of care. MoxDuo(TM) IV is one of three Dual-Opioid(TM) products that also include immediate-release (IR) and controlled release (CR) oral formulations," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

QRxPharma's MoxDuo(TM) products are the only combination opioids in commercial development. Extensive clinical studies have shown Dual-Opioids(TM) to provide better pain relief with significantly fewer side effects.

This double blind, active controlled study will determine: (1) whether MoxDuo(TM) IV has fewer opioid-related adverse events than morphine alone at equianalgesic doses and (2) whether the maximum analgesic effect of MoxDuo(TM) IV is superior to morphine alone.

The study is being conducted at the Cologne-Merheim Medical Center, a part of Witten/Herdecke University, and Cologne University Hospital, both in Cologne, Germany.


'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
2. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
6. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
7. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
8. Medicago initiates work on Swine Flu strain
9. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
10. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 Having added two ... latter part of 2014, ITRA Global proudly announced recently ... International Tenant Representative Alliance, based in the United States, ... tenants and occupiers of commercial real estate. , ... firm in Poland that exclusively advises occupiers of office ...
(Date:3/25/2015)... the HAGUE, Netherlands , March 25, 2015 /PRNewswire/ ... therapy for chronic gastro-esophageal reflux disease (GERD) in the ... Surgery . 2015; 157(3):556-567 ], establishing the long ... The study included 25 patients with severe ... taking prescribed daily proton pump inhibitor (PPI) medication for ...
(Date:3/25/2015)... 25, 2015 /CNW/ - The Gairdner Foundation is ... Canada Gairdner Awards, recognizing some of the most significant ... Among the world,s most esteemed medical research ... and provide a $100,000 (CDN) prize to each scientist for ... of research and innovation across the country, inspiring ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 ... has released today version 4 of Face2Gene, ... Novel Analysis from computers, as well as mobile devices. ... patterns of human malformations to present comprehensive and up-to-date ... the Annual Clinical Genetics Meeting, ACMG 2015, in ...
Breaking Biology Technology:International Organization Expands its Global Reach to Warsaw, Poland 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... Conventional wisdom would say that blocking a hole would prevent light ... opposite to be true. A research team has found that placing ... does not stop the light at all, but rather enhances its ... that can occur at very small scales, electrical engineer Stephen ...
... Calif., Nov. 22, 2011 Molecular diagnostics company ... board with the appointment of three initial members: ... M.D., Ph.D., and Dr. Gregory Tsongalis, Ph.D., H.C.L.D., ... science, laboratory medicine and the commercial market related ...
... Nov. 22, 2011 AtheroNova Inc. (OTCBB: AHRO) ... and development of compounds to regress atherosclerotic plaque, ... Associate Professor of Medicine, Division of Cardiology at ... at the 2011 American Heart Association (AHA) Scientific ...
Cached Biology Technology:Blocked holes can enhance rather than stop light going through 2Blocked holes can enhance rather than stop light going through 3GenturaDx Announces Formation of Scientific Advisory Board 2AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... and observing technologies are giving marine conservationists a fish-eye ... are contributing to declining fish populations, according to a ... only such limited data as stock counts and catch ... and lead author of the study published in the ...
... School of Public Health have for the first time ... in multiple mosquito species capable of stopping the development ... in humans. By silencing the gene, caspar, the ... malaria-causing parasite in Anopheles gambiae , A. ...
... in the atmosphere may play a profound role in ... particles -- called aerosols -- have long struggled to ... new detection technique and a new satellite instrument developed ... help ease the struggle. Some types of small ...
Cached Biology News:New tracking tags are providing fish-eye views of ways to manage depressed fisheries 2Malaria immunity trigger found for multiple mosquito species 2New aerosol observing technique turns gray skies to blue 2New aerosol observing technique turns gray skies to blue 3New aerosol observing technique turns gray skies to blue 4
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Biology Products: